DIVISION OF CARDIOLOGY - summary OFWEEKLY ROUNDS SCHEDULE

MONDAY, FEBRUARY 15 to FRIDAY,FEBRUARY 19, 2016

Monday, February 15:

8:00-9:00 / Cardiovascular Grand Rounds No Rounds – Family Day
12:00-1:30 / Adult Congenital Cardiac Surgery Rounds - Videoconference from Toronto
No Rounds – Family Day

Tuesday, February 16:

7:00-8:00 / B6-115 UH
OTN Event #
51365379 / Complex Revascularization Rounds Presenters: CV Surgeons & Interventional Cardiologists
Faculty Supervisors: D. Nagpal & P. Garg
Case-based presentation and discussion
Learning Objectives:
1. To develop a systematic approach to interpretation of coronary angiograms.
2. To discuss interesting case examples and their management.
3. To apply an evidence-based approach to complex revascularization cases in order to improveoutcomes.
2:00-5:00 / B6-128 UH / DIDACTIC EDUCATION SESSIONS:
2:00-3:00 / B6-128 UH / PACEMAKER SYMPOSIUM Presenter: P. Leong-Sit

Wednesday, February 17:

8:00-9:00 / B6-115 UH
OTN Event #
50202106 / EP Rounds: Device Rounds Presenters: Attendings & Fellows
Learning Objectives:
1. To develop a systematic approach to device tracings.
2. To discuss interesting case examples.
3. To review programming features and troubleshooting.
12:00-1:00 / B6-115 UH &
C2-504VH
OTN Event #
46453618 / Adult Congenital Cardiac Teaching Rounds -Videoconference from Toronto
Presenter: L. Mertens
Title of Presentation: Single Ventricle Assessment

Thursday, February 18:

7:00-8:00 / B6-115 UH
B2-122 VH
OTN Event#
47772081 / Cardiac Cath/Interventional Rounds Presenter: P. Garg
Title of Presentation: TBA
Learning Objectives: TBA
8:00-9:00 / B6-128 UH / Graphics Rounds: ECHO Presenter: D. McCarty
6:30 pm / 583 Eclipse Walk, London / Electrophysiology Journal Club Attendance open to Electrophysiologists and EP Fellows, Residents and EP Research Staff. RSVP to Charlene Grass (Ext. 33830 or email ).
Topic: ETOH and AF
Papers to be reviewed:
1. Kareem Ballut: Alcohol Consumption and Risk of Atrial Fibrillation – A Meta-Analysis S. Kodama, et al. J Am Coll Cardiol 2011;57:427-36.
2. Ali Kazemi Saeid: Alcohol Consumption and Risk of Atrial Fibrillation – A Prospective Study andDose-Response Meta-Analysis Larsson et al. J Am Coll Cardiol 2014;64:281-9.
3. Tuan Nguyen: Impact of Alcohol Consumption on Substrate Remodeling and Ablation Outcome ofParoxysmal Atrial Fibrillation Y. Qiao et al. J Am Heart Assoc 2015;4:e002349.
4. Anthony Tang: Holiday Heart Syndrome Revisited after 34 Years D. Tonelo, et al. Arq Bras Cardiol. 2013;101(2):183-189
Learning Objectives:
1. To systematically appraise and assimilate scientific evidence from journal articles and how it can be applied to clinical practice.
2. To stay up to date with advances in biomedical and clinical evidence and to facilitate self-learning and professional development.
3. To provide a forum for discussion and peer-review between health care professionals on current best practice that is evidence based.

Friday, February 19:

8:00-9:00 / B6-128 UH / EP Tracing Rounds:Case Presentations with ECGand Intra-cardiac tracings
Presenters: Attendings Fellows
Learning Objectives:
1. To develop a systematic approach to EP tracings.
2. To discuss interesting case examples.
3. To review electrophysiology principles and concepts.

Some of these educational activities/rounds are an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the Division of Cardiology Education Committee - Western University.

Supported by unrestricted grants-in-aid provided by:

Aegerion Pharmaceuticals (Juxtapid (lomitapide)), Amgen Canada Inc. (Repatha), AstraZeneca Canada Inc. (Brilinta (Ticagrelor)),

Bayer HealthCare Pharmaceuticals (XARELTO® rivaroxaban tablet), Boehringer Ingelheim (Canada) Ltd. (Pradax (dabigatran), Twynsta (telmisartan/amlodipine)), Bristol-Myers Squibb Canada & Pfizer Canada Inc., (Eliquis (apixaban)), Medtronic of Canada Inc., Merck (Ezetrol, Olmetec®), Novartis Pharmaceuticals of Canada Inc. (Entresto), Servier Canada Inc. (Coversyl)